Medivis has sold its portfolio products to DOC Generici, leading to a strategic collaboration focused on ophthalmic innovations.

Information on the Target

Medivis is a prominent pharmaceutical company based in Catania, Italy, established in 2000. It specializes in the research, development, and marketing of ophthalmic products and is recognized for its innovative approaches in the field. Medivis has developed 18 international patents, showcasing its commitment to advancing drug delivery systems and nanotechnology applications specific to ophthalmology. Their pioneering work has focused on the potential of antiseptics for topical use and the modulation of the microbiome in therapeutic ophthalmology.

Recently, Medivis has decided to refocus its operations on research and development following the sale of its product portfolio, Nuova Oftalmica, to DOC Generici. As part of this transition, Medivis will engage in a collaboration with DOC Generici to create innovative ophthalmic products, strengthening its research capabilities.

Industry Overview in Italy

The pharmaceutical industry in Italy plays a crucial role in the national economy, characterized by a robust market for both patented and generic medications. Italy is home to a thriving ecosystem of biotechnology firms and research instit